

THE LIVER GROUP
ANNUAL REPORT AND ACCOUNTS
FOR THE YEAR ENDED 31 DECEMBER 2013



THE LIVER GROUP

CONTENTS

Association Information	1
Report of the Trustees	2-4
Chairman's Report	5
Independent Auditor's Report	6-7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10-17

THE LIVER GROUP
ASSOCIATION INFORMATION
FOR THE YEAR ENDING 31 DECEMBER 2013

Trustees: Sarah Bates
David Clifford
Ciáran Devane (Co-opted)
Sue Eggleton
Kay Glendinning MBE
Prof Humphrey Hodgson FRCP, F Med Sci
Prof David Kerr CBE
Prof Sir Roger Penrose OM FRS
Clare Selden

Principal office: UCL Institute of Liver and Digestive Health - The Liver Group
UCL - Royal Free Hospital Campus
University College Medical School
Upper Third Floor
Rowland Hill St
Hampstead
London NW3 2PF

Charity registration number: 1024533

Bankers: HSBC
Oxford Circus Branch
London W1A 1EZ

CCLA Investment Management Ltd
80 Cheapside
London EC2V 6DZ

Auditors: Simpson Wreford & Co
Wellesley House
Duke of Wellington Avenue
Royal Arsenal
London SE18 6SS

THE LIVER GROUP**TRUSTEES' REPORT****FOR THE YEAR ENDING 31 DECEMBER 2013**

The Trustees submit their annual report and the audited financial statements for the year ended 31 December 2013. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" issued in 2005 in preparing the annual report and financial statements of the Charity which have been prepared under section 132 of the Charities Act 2012. The organisation is a Charity constituted under a Trust Deed dated 28 May 1993.

The administrative information set out on page 1 forms part of this report.

Objectives and activities

The objects of the charity are:

- i) The relief of patients suffering from disease of the liver and genetic defects affecting the liver
- ii) The promotion of research into the causes and treatment of diseases of the liver on terms that the results of such research are published.

The principal activity of the Charity currently is the project being conducted to develop an artificial liver. The artificial liver project is being carried out with the funds raised for the continuing "Liver for Life" Appeal.

The Board of Management comprises nine Trustees, eight elected, one co-opted. The members are able to draw on relevant board experience in board deliberations. The Board is collectively responsible for the competent management of the organisation in accordance with its objectives which are set out in the Trust Deed. The Board meets twice a year to monitor the organisation's strategy and activities.

The Charity does not have any employees and its day to day activities are carried out by University College London under the supervision of two Trustees. If the need arose to appoint a new Trustee the remaining Trustees would identify and appoint an appropriate person. The current Trustees are responsible for the induction of any new trustee which involves making them aware of the Trustees' responsibilities, the governing documents, administrative procedures and the history and philosophical approach of the charity. The Trustees have agreed a position that should any profits arise from the intellectual property in the research being carried out by the team, and in conjunction with the various other parties involved in that work, the Charity may/would be entitled to up to 50% of such amounts.

Achievements and performance

- Research output, intellectual property gained and achievement of milestones towards moving the Bioartificial Liver project from the bench to the bedside.
- Administrative charitable activities are limited to fundraising for the research endeavour. This is achieved by written applications to known grant giving organisations, small and large companies via the CEOs or other appropriate individual or wealthy individual donors. The Charity also has a web-page with an opportunity to donate via CAF. £104,076 (2012 £114,819) was raised in this financial year from donations; other income was generated from interest earned on cash deposits.
- Indicators of achievements are success in the research aims and, in addition, the total funds raised in a particular year. These rarely exceed our expenditure for the year.

THE LIVER GROUP**TRUSTEES' REPORT****FOR THE YEAR ENDING 31 DECEMBER 2013****(Continued)**

- The Charity is one of many sourcing the same research funding; given the difficult position most UK universities find themselves in, there is increasing competition for funds. Until government resources fill the gap between the costs and current funding of medical research the Charity's efforts will become more difficult each year. Notwithstanding this difficult climate, the Charity continues to explore every avenue to increase funding from grants and donations.

Financial review

The organisation is funded mainly by donations. They are a mixture of individual, corporate and charitable trust donations.

The majority of funds are spent on paying the salaries of researchers, as well as the required consumables and equipment for the research to continue. As evidenced by the publications, the Charity's current aim to develop a bio-artificial liver machine (BAL) has moved forward from the medium scale to human scale. The following period will see a scale up towards clinical scale for this machine. Each of these steps is associated with a considerable increase in research personnel, consumable and equipment expenditure.

Except for such funds as the Trustees consider prudent to maintain for the purpose of management and administration of the Charity for the foreseeable future, all unrestricted funds are applied for the purposes of the "Liver for Life" project and the general charitable objects of the Charity.

As at 31 December 2013 the unrestricted fund had a committed surplus of £496,489 (2012 – £438,398), and the restricted fund had been cleared as at the end of the year. The Charity's unrestricted fund is already committed to existing research and PhD students and their necessary consumables.

As the bio-artificial liver project nears clinical scale and development for clinical trial, the costs are rapidly increasing necessitating considerable further fund-raising.

Risk management

The Trustees confirm that there are ongoing processes for identifying, evaluating and managing significant risks faced by the organisation.

Public benefit

All the donations made by the Charity were in furtherance of the Charity's long term objective of providing the relief of patients suffering from diseases of the liver and genetic defects affecting the liver, and promoting research into the causes and treatment of liver disease. The Charity has complied with section 17 of the Charities Act 2012 having due regard of the public benefit guidance published by the Commission.

Plans for future periods

The Charity aims to continue its medical research goals, at a pace commensurate with funding opportunities. With appropriate funding it sees the bio-artificial liver machine project reach the clinical trial assessment within five years.

THE LIVER GROUP
TRUSTEES' REPORT
FOR THE YEAR ENDING 31 DECEMBER 2013
(Continued)

Statement of Trustees' responsibilities

The Trustees are responsible for preparing the Trustees' Report and the financial statement in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2012, the Charity (Accounts and Reports) Regulation 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditors

A resolution to re-appoint Simpson Wreford & Co as auditors will be proposed at the next AGM.

The report was approved by the Trustees on 13 October 2014



Humphrey Hodgson
Trustee

THE LIVER GROUP
CHAIRMAN'S REPORT
FOR THE YEAR ENDING 31 DECEMBER 2013

The work of the scientists of the Liver Group has concentrated this year on pushing forward the development of our bioartificial liver being funded by our Wellcome Trust Translational Award, 2013 being the first full year of that grant funding; and on a parallel project that will in due course allow the applicability of the liver machine to be extended by developing techniques for the bioartificial liver devices to be kept frozen but 'at the ready' available whenever required. In last year's report I outlined the aims of the Wellcome-funded project, which builds on years of basic research funded in large part by the Liver Group Charity: we are required to 'tie down' the design and manufacture of our bioartificial liver device based on cultured liver cells, which will supplement liver function in patients with liver disease, thus buying time for recovery to take place or for liver transplantation to be arranged. Much of the year has been spent in perfecting the 'scaling-up' process, so now we can prepare a liver device containing over seventy billion cells at the ready, held in millions of small alginate beads, in a chamber through which a patient's blood plasma can be circulated. We have also progressed with refinements to the circuit, for instance developing and incorporating filters to prevent cell debris, or DNA derived from the cultured cells, escaping into the circuit and passing into the patient's circulation.

The parallel project on cryopreservation, holding the alginate-encapsulated cells frozen at very low temperatures, is progressing well; the scientific requirement is to develop further a process which is well recognised and in routine use – the freezing of small numbers of separated cells – to allow the freezing of huge numbers of cells which, in their encapsulated form, have a complex 3-dimensional structure. This work has involved collaboration with cryobiologists, mathematicians to model heat and cold transfer, and industry; it is another example of the way in which the Charity works, raising funds so that pilot, proof-of-principle studies can be performed, and then peer-reviewed grant funds raised.

One particular means of applying the Charity's funds has been to part-fund PhD projects, either sharing the payment of the candidate's stipend or supporting the consumable costs of their experiments. In this way the laboratory supports one or more PhD students in each of the three years of their course, and they combine important contributions to the science produced by the laboratory with acquisition of rigorous scientific skills.

The grant-raising activities of the Liver Group continue to be of major importance to allow us to take on new projects – though always allied to the aims of treating liver disease better; one of our PhD students is developing the approach I alluded to briefly last year, a 'bolt-on' to the bioartificial liver circuit to combat sepsis, and that work, initially funded only by the Liver Group, has now attracted further funding from two medical charities.

We remain as always immensely indebted to those who have and who continue to support our work. I should thank also two of our Trustees, Professor David Kerr and Professor Roger Penrose, who have kindly agreed to take over, jointly, as Patrons of the Charity.



Humphrey Hodgson
Chairman

INDEPENDENT AUDITOR'S REPORT
TO THE TRUSTEES OF THE LIVER GROUP
FOR THE YEAR ENDED 31 DECEMBER 2013

We have audited the financial statements of The Liver Group for the year ended 31 December 2013 which comprise the Statement of Financial Activities, the Balance Sheet and the related notes. The financial reporting framework which has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

This report is made solely to the Trustees, as a body, in accordance with Section 144 of the Charities Act 2012 and the regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees as a body, for our audit work, for this report or for the opinions we have formed.

Respective responsibilities of the Trustees and Auditors

As explained more fully in The Trustees' Responsibilities Statement set out on page 4, the trustees are responsible for the preparation of financial statements which give a true and fair view.

We have been appointed under section 144 of the Charities Act 2012 and report in accordance with regulations made under section 154 of that act. Our responsibility is to audit and express an opinion on the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK & Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit

An audit involves obtaining evidence about amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the charity's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the trustees; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustee's Report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the Charity's affairs as at 31 December 2013 and of its incoming resources and application of resources in the year then ended, and
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (applicable to Smaller Entities); and
- have been prepared in accordance with the Charities Act 2012.

INDEPENDENT AUDITORS' REPORT
TO THE TRUSTEES OF THE LIVER GROUP
FOR THE YEAR ENDED 31 DECEMBER 2013
(Continued)

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities Act 2012 requires us to report to you, in our opinion:

- the information given in the Trustees' Annual Report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

SIMPSON WREFORD & CO
Statutory Auditors
Wellesley House
Duke of Wellington Avenue
Royal Arsenal
London SE18 6SS

Dated: 13 October 2014

THE LIVER GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2013

	Notes	Unrestricted Funds	Restricted Funds	Total 2013	Total 2012
		£	£	£	£
Incoming resources	2				
<i>Incoming resources from generating funds</i>					
Voluntary income		96,576	7,500	104,076	114,819
Investment income		2,246	-	2,246	4,333
Incoming resources for the year		98,822	7,500	106,322	119,152
Resources expended	3				
Charitable activities		37,431	7,500	44,931	130,009
Governance costs		3,300	-	3,300	4,165
		40,731	7,500	48,231	134,174
Net outgoing resources for the year		58,091	-	58,091	(15,022)
Transfers		-	-	-	-
Fund balances at 1 January 2013		438,398	-	438,398	453,420
Fund balances at 31 December 2013		496,489	-	496,489	438,398

THE LIVER GROUP
BALANCE SHEET AT 31 DECEMBER 2013

	Notes	2013 £	2012 £
Current assets			
Debtors	5	2,500	-
Cash at bank and in hand		<u>583,910</u>	<u>541,576</u>
		586,410	541,576
Less: Creditors			
Amounts falling due within one year	6	<u>(89,921)</u>	<u>(103,178)</u>
Net assets		<u><u>496,489</u></u>	<u><u>438,398</u></u>
Financed by			
Unrestricted funds		496,489	438,398
Restricted funds	7	<u>-</u>	<u>-</u>
Total funds		<u><u>496,489</u></u>	<u><u>438,398</u></u>

These accounts have been prepared in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

Approved by the Trustees on 13 October 2014

THE LIVER GROUP**NOTES TO THE FINANCIAL STATEMENTS****FOR THE YEAR TO 31 DECEMBER 2013****1. Accounting Policies****Basis of accounting**

The accounts have been prepared under the historical cost convention and in accordance with applicable Accounting Standards, the Charities Act 2012 and the Statement of Recommended Practice "Accounting for and reporting by Charities" (SORP 2005), and the Financial Reporting Standard for Smaller Entities (effective April 2008).

Voluntary income

Donations represent amounts received during the period and arise within the United Kingdom. Covenant and Gift-Aid income is included in gross attributable tax recoverable.

Investment income

Interest receivable is credited to income in the period in which it is earned and is included gross of attributable tax recoverable.

Charitable activities

Charitable activities are the research expenditure incurred on behalf of the Charity and recharged to The Liver Group by University College London (UCL). These are charged to the statement of financial activities (SOFA) on an accruals basis. This expenditure includes amounts paid for capital equipment and laboratory infrastructure which are regarded as expenditure in these accounts

Governance costs

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charity and include the costs related to the statutory audit.

Allocation of overhead and support costs

All overhead and support costs relate to governance costs and have been allocated as such (note 3).

Liabilities

Liabilities are recognised in the accounts where there is an obligation to transfer economic benefit.

Fund accounting

Total funds comprise the accumulated surplus or deficit on the statement of financial activities. Unrestricted funds are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity. Restricted funds are subject to specific restricted conditions imposed by donors. The purpose and use of these funds are set out in the notes to the accounts.

Taxation

The Charity is not liable to income tax on income derived from its charitable activities as it falls within the various exemptions available to registered charities.

The Charity is not registered for value added tax (VAT) and is therefore unable to reclaim the input tax it suffers on its purchases. Expenditure in the accounts is therefore shown inclusive of VAT where appropriate.

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2013

2. Incoming resources

	2013	2012
	£	£
Voluntary income		
The Peter Stebbings Memorial Trust	64,651	59,652
The Garfield Weston Foundation	16,667	33,333
Salters Charitable Foundation	8,467	-
Tom and Sheila Springer Charity	7,500	7,313
The Bernard Sunley Charity Foundation	1,500	-
The Catherine Cookson Charitable Trust	1,000	-
Smiths Group Plc	1,000	-
N Smith Charitable Foundation	1,000	-
The Coutts Charitable Trust	500	500
The Arnold Burton 1998 Charitable Trust	500	500
Bank of England	500	500
Sundry Contributors	477	-
The Chandris Foundation	250	250
Anonymous Donations	64	121
The Gerald Palmer Eling Trust	-	3,500
Triplow Charitable Trust	-	2,500
The Fishmongers Company	-	1,750
The Astor Foundation	-	1,500
The Oakdale Trust	-	1,000
Armourers & Brasiers' Gauntlet Trust	-	750
Reuben Foundation	-	500
Rowan Bentall Charitable Trust	-	500
Yorkshire & Clydesdale Bank Foundation	-	400
The Fitton Trust	-	250
	<u>104,076</u>	<u>114,819</u>
Investment income		
Bank interest	<u>2,246</u>	<u>4,333</u>

3. Resources expended

	2013	2012
	£	£
Charitable activities		
Staff costs (employed on fixed term UCL contracts)	32,133	92,149
Research consumables and laboratory	<u>12,798</u>	<u>37,860</u>
	<u>44,931</u>	<u>130,009</u>
Governance costs		
Auditors' remuneration (including VAT)		
Accounting	1,020	1,104
Printing, postage and stationery	300	-
Legal fees (Trade-marking etc.)	-	920
Audit	<u>1,980</u>	<u>2,141</u>
	<u>3,300</u>	<u>4,165</u>

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2013

The average weekly number of employees of UCL working for The Liver Group during the year was 4 (2012: 4). At the year end there were 4 employees of UCL working on The Liver Group research. In addition there were 3 PhD students paid a stipend under a 3 year studentship scheme. There were no employees with remuneration above £60,000 for the year ended 31 December 2013

None of the trustee's received any remuneration and their expenses reimbursed during the year amounted to £Nil (2012: £Nil)

4. Funding requirements

'Liver for Life' Appeal – What we require to fund (2014-2018)

Research salaries and studentships (including consumables) over 5 years

Senior Fellowship/Lectureship (1 required)	£341,630
Post-Doctoral Research Fellowship (2 required)	£631,285
<i>Post-Doctoral Research Fellowship per covenanted year</i>	<i>£126,257</i>
PhD Studentship (5 total required, 1 per year)	£484,309
Graduate Research Assistantship (3 required)	£926,846

Equipment over 5 years eg.

Small bench-top recurrent equipment	£1,000	-	£10,000
Major equipment	£10,000	-	£100,000
State-of-the-art preparative and analytical instruments	£50,000	-	£200,000

TOTAL FUNDRAISING GOAL

£2,694,070

The Liver Group is enthusiastic to establish named posts to acknowledge donations from individuals or organisations.

These projections do not form part of audited accounts of the charity.

5. Debtors

	2013	2012
	£	£
Accrued Income	2,500	-
	<u>2,500</u>	<u>-</u>

6. Creditors

	2013	2012
	£	£
Accruals	9,875	4,375
Deferred Income	58,935	46,493
Amounts due to UCL	21,111	52,310
	<u>89,921</u>	<u>103,178</u>

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2013

7. Restricted funds

	Balance at 1 Jan 2013	Incoming Resources	Resources Expended	Transfers	Balance at 31 Dec 2013
	£	£	£	£	£
Tom & Sheila Springer Charity	-	7,500	(7,500)	-	-
	<u>-</u>	<u>7,500</u>	<u>(7,500)</u>	<u>-</u>	<u>-</u>

Restricted funds have arisen from donations received by the Charity from the donors detailed above.

The donations from Tom & Sheila Springer Charity were towards the salary of a PhD student. Each fund is applied in accordance with the restrictions imposed.

8. Other professional services provided by the auditors

In common with many other charities our size and nature we use our auditors to prepare and assist with the preparation of the financial statements.

9. Controlling Party

The ultimate controlling party of the charity is the board of Trustees.

10. Related party transactions

There were no related party transactions identified during the year.

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2013

We are grateful to the following for donations to the “Liver for Life” Appeal:

Anonymous	C W Mills
Armourers & Brasiers Gauntlet Trust	D M Wilton
Associated British Ports	Dako Limited
BAE Systems	Economist Plc
Bank of England	EJH Stephenson (Deceased) Charitable Trust
Barclays Bank (Knightsbridge Limited)	Friends Provident
Billingsgate Christian Mission Charitable Trust (The Fishmongers’ Company)	Glaxo Plc (GlaxoKlineSmith)
Boots Plc	Guardian Royal Exchange Plc
Bowring Plc	HJ Heinz Co Ltd Charitable Trust
Brian Wright Esq	Hon C A Pearson’s Charity Trust
British Aerospace	Honeywell Plc
BS & IP Aynscombe	IBJ
BTR Plc (Invensys)	Jardin Insurance Services Ltd
C E Health Plc	John Taylor Funeral Service
CAF Bank	J Feinstein
C Collins	In Memoriam
Charles Littlewood Charitable Trust	J H Turner
Citibank	Jardine Insurance Services Ltd
Clydesdale Bank/Yorkshire Bank	KPMG
Commercial Union	Laing, London
Communis Plc	Land Securities Plc
Conoco Philips	Life Technologies
Cookson Group Plc	Lloyds TSB Bank Plc
Cooper Charitable Trust	M E Rickman Trust
Council of Forte Trust Fund	Mars UK Corporate Services Ltd
Courage Plc	Menzies Group
Coutts and Co	Morgan Crucible Company Plc
Coutts Charitable Trust	Morgan Grenfell (Deutsche Bank)

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2013

We are grateful to the following for donations to the “Liver for Life” Appeal, continued:

Mr & Mrs Sutcliffe	Sunlife Assurance Plc (AXA Sunlife)
N Smith Charitable Settlement	The Arnold Burton 1998 Charitable Trust
New Brunswick Plc	The Astor Foundation
Pamela Godfrey	The Barbinder Trust
Peter Stebbings Memorial Trust	The Bergqvist Charitable Trust
Pfizer Ltd	The Bernard Sunley Charitable Foundation
Pharmaceutical Brand Consultancy Int	The Bowerman Memorial Trust
Pricewaterhouse Coopers Plc	The Bryan Guinness Charitable Trust
Racial Charitable Trust	The Catherine Cookson Charitable Trust
R C & D Ward	The Chandris Foundation
Reuben Charitable Trust	The Childwick Trust
Richard Wilkinson Esq	The Clothworkers’ Foundation
Rio Tinto Plc	The Dunhill Medical Trust
Robert Fleming Holdings Ltd	The Eranda Foundation
Royal London Insurance Ltd	The Fitton Trust
Rowan Bentall Charitable Trust	The Garfield Weston Foundation
Royal London Group	The Gerald Palmer Eling Trust
Royal London Insurance Ltd	The Haberdashers Company
Rudolf Wolff & Co Ltd	The Hamamelis Trust
S&I Donald	The Harnett Charitable Trust
Saddlers’ Company	The John Ellerman Foundation
Schroders Plc	The Mary Webb Trust
Seagrams Distillers Plc	The Mercers Company
Securicor Plc (G4S)	The Oakdale Trust
Smiths Group	The Paul Balint Charitable Trust
Societe Generale United Kingdom Charitable Trust	The Really Useful Group Ltd
Special Trustees for Hammersmith & Acton Hospitals	The Saddlers’ Company
Steel Charitable Trust	The Sobell Foundation

THE LIVER GROUP

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR TO 31 DECEMBER 2013

We are grateful to the following for donations to the “Liver for Life” Appeal, continued:

The Stella Symons Charitable Trust

The Telegraph Plc

The Thomas Sivewright Catto Charitable Settlement

Thomson Corporation

Thriplow Charitable Trust

TI Group

Tom & Sheila Springer Charity

Tomkins Plc

Vauxhall Plc

Violet M Richards Charity

Yorkshire and Clydesdale Bank Foundation

Wilkinson Hardware Stores Ltd

William & Mabel Morris Charitable Trust

THE LIVER GROUP**NOTES TO THE FINANCIAL STATEMENTS****FOR THE YEAR TO 31 DECEMBER 2013****Publications arising from the work of The Liver Group Charity in 2013**

Protein engineered variants of hepatocyte growth factor/scatter factor promote proliferation of primary human hepatocytes and in rodent liver.

Ross J, Gherardi E, Mallorqui-Fernandez N, Bocci M, Sobkowicz A, Rees M, Rowe A, Ellmerich S, Massie I, Soeda J, Selden C, Hodgson H.

Gastroenterology. 2013 Apr; 142(4):897-906. PMID: 22178588

Storage temperatures for cold-chain delivery in cell therapy: a study of alginate-encapsulated liver cell spheroids stored at -80°C or -170°C for up to 1 year.

Massie I, Selden C, Hodgson H, Fuller B.

Tissue Eng Part C Methods. 2013 Mar;19(3):189-95. Epub 2013 Sep 7. PMID: 22834979

Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepatocyte differentiation and functionality.

Ramasamy TS, Yu JS, Selden C, Hodgson H, Cui W.

Tissue Eng Part A. 2013 Feb;19(3-4):360-7. Epub 2013 Sep 24. PMID:23003670

Presentations at national and international scientific meetings

Developing a Controlled Vitrification Machine (Liquidus Tracker) and associated low toxicity CPA solutions to cryopreserve encapsulated liver cell spheroids cells for a bioartificial liver device. E.Puschmann, C.Selden, H Hodgson, M.Winslet and B.Fuller 49th Annual Meeting of the Society for Cryobiology June 2013

Towards A Clinical Bioartificial Liver Machine For Acute Liver Failure

C Selden, E Erro, W Spearman, D Kahn , M Miller, A Figaji, J Bundy,C Legallais , H Hodgson

Presented at the European Society of Artificial Organs

Int J Artif Organs 2013; 35(8): 555 – 587